Key Takeaways
- Scotiabank (BNS) reported robust Q4 2025 earnings, with revenue reaching C$9.80 billion, surpassing estimates of C$9.43 billion, and adjusted EPS of C$1.93 against an estimated C$1.84.
- Eli Lilly (LLY) received a significant price target increase from BofA Global Research, which raised its target to $1286 from $950, driven by the strength of its GLP1 franchise.
- Pfizer (PFE) saw Citigroup resume coverage with a Neutral rating and a $26 target price, balancing operational efficiencies with anticipated medium-term headwinds.
- US equity markets are poised for a modestly higher open, though broader market sentiment indicates some mixed signals in futures trading.
- Italy's Producer Price Index (PPI) for October registered a month-over-month decline of 0.4% and a year-over-year increase of 0.2%.
Scotiabank Exceeds Q4 Expectations
Bank of Nova Scotia (BNS), commonly known as Scotiabank, announced strong fourth-quarter 2025 earnings, outperforming analyst expectations for both revenue and adjusted earnings per share. The Canadian banking giant reported revenue of C$9.80 billion, exceeding the estimated C$9.43 billion. Adjusted earnings per share came in at C$1.93, higher than the analyst consensus of C$1.84.
Despite the positive top-line performance, the bank's CET1 ratio stood at 13.2%, slightly below the estimated 13.3%. Provisions for credit losses also came in higher than anticipated at C$1.11 billion, compared to an estimated C$1.08 billion. Scotiabank's earnings kick off the reporting season for Canada's major banks, setting a high bar for its peers.
Eli Lilly Sees Significant Price Target Boost
Pharmaceutical giant Eli Lilly and Co. (LLY) received a substantial upgrade to its price target from BofA Global Research. The firm raised its target to $1286 from $950, maintaining a Buy rating on the stock. This significant increase is primarily attributed to the robust performance and future potential of Eli Lilly's GLP1 franchise, including drugs like Zepbound/Mounjaro (tirzepatide), which dominates the obesity and diabetes market.
BofA also highlighted the accelerated timeline for the launch of Eli Lilly's oral GLP1 medication, orforglipron, now expected in March 2026 following an FDA Commissioner's National Priority Voucher.
Pfizer Coverage Resumed by Citigroup
Citigroup has resumed coverage of Pfizer Inc. (PFE), assigning a Neutral rating and setting a price target of $26. The analyst's balanced view acknowledges Pfizer's operational efficiencies and policy certainty, which are weighed against "substantial" medium-term headwinds, particularly from pressures associated with Medicare Part D. This re-initiation of coverage provides a fresh perspective on the pharmaceutical company's outlook.
Mixed Signals for US Market Open
US equity markets are anticipated to open modestly higher today. However, broader market sentiment appears mixed, with some futures indicating a slight dip in early Tuesday trading following a softer start to December on Monday. European bourses have shown firmer trends, contributing to the cautiously optimistic outlook for the US market open.
Italian Producer Prices Decline in October
Italy's Producer Price Index (PPI) for October showed a month-over-month decline of 0.4%, following a previous increase of 0.2%. On a year-over-year basis, the PPI increased by 0.2%, a slowdown from the prior 1.5% gain. This data point provides insight into inflationary pressures at the producer level within the Italian economy.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.